Riddhi Siddhi Gluco Biols reported a jump in revenue for Q2 FY26 following the integration of Cargill India’s starch division, though net profits fell compared to the previous year. The company has successfully reached 75% public shareholding compliance. Investors must weigh these operational shifts against an ongoing SEBI-related market restraint active until December 2026.
Riddhi Siddhi Gluco Biols Q2 Financials and Strategic Update
Standalone Revenue: Rs 58.43 Crore | Consolidated Profit: Rs 6.85 Crore
Reader Takeaway: Revenue surged via acquisitions, but profit margins faced year-over-year pressure amid ongoing regulatory market restrictions.
What just happened
Riddhi Siddhi Gluco Biols reported its financial results for the quarter ended September 2026. Standalone revenue jumped to Rs 58.43 crore from Rs 25.27 crore a year earlier, while consolidated revenue rose to Rs 66.49 crore. Despite the top-line growth, standalone profit after tax dipped to Rs 17.68 crore from Rs 23.95 crore, and consolidated profit declined to Rs 6.85 crore from Rs 13.75 crore in the corresponding period last year.
Why this matters
The growth in top-line figures reflects the successful integration of the starch division acquired from Cargill India, effective April 2026. Additionally, the company acquired a 26% stake in Clean Max Pluto Solar Power LLP in July 2026, signaling a shift toward energy diversification. The company also reached a significant corporate milestone by reducing promoter shareholding to 75%, complying with Minimum Public Shareholding (MPS) norms through a stake sale by Vital Connections LLP.
Risks to watch
A primary concern remains the regulatory restraint order imposed by the Securities Appellate Tribunal (SAT) and upheld by the Supreme Court, which bars the company from dealing in the securities market until December 23, 2026. Shareholders should also track a pending income tax appeal regarding Rs 3.08 crore in disputed additions, currently under review by the Income Tax Appellate Tribunal in Ahmedabad.
What to track next
Investors should monitor the expiration of the market restraint period in December 2026 and the operational impact of the new starch division as it fully contributes to the company's bottom line in upcoming quarters.